( d genericpharmaceuticals. We are stren...)Data to be presented at AAN Meeting -Study results of drug,candidate for MS,Health

d generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

###

Media contacts

Christine Cascio

Novartis Pharmaceuticals Corporation

+1 862-778-8026 (direct)

+1 917-449-9982 (mobile)

christine.cascio@novartis.com

Emily Baier

Feinstein Kean Healthcare

+1 617-761-6708 (direct)

+1 617-921-4980 (mobile)

emily.baier@fkhealth.com

AAN 2007 -FTY720 Posters

1) [P06.085] Oral FTY720 in Relapsing Multiple Sclerosis (MS): Impact on Patient-Reported Depression, as Measured by the Beck Depression Inventory II in a 6-month, Placebo-Controlled Phase II Study

Date: Thursday, May 3, 2007 7:00 AM

Location: Exhibit Hall A - Poster Sessions VI: Multiple Sclerosis and Related Diseases: Therapeutics (7:00 - 10:00 AM)

Objective: To examine the effect of FTY720 on patient-reported depression. BACKGROUND: Current disease-modifying MS therapies have a variable impact on depression, a common symptom in MS. FTY720, a new oral sphingosine-1-phosphate receptor modulator, has shown reductions in relapse rate of >50% and MRI activity of up to 80% vs placebo (PL) during a 6-month, Phase II study in relapsing MS (Kappos et al. N Engl J Med 20
'"/>

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
2. Data supporting three Antisoma programmes presented at AACR
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
6. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting